Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Sporadic Papillary Renal Cell Carcinoma: early-phase trial registry

1 of 1 indexed Sporadic Papillary Renal Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Sporadic Papillary Renal Cell Carcinoma: 1 US clinical trial tracked, 1 recruiting.

Sporadic Papillary Renal Cell Carcinoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 1 of these trials.

Enrollment posture brief

Registry condition sporadic-papillary-renal-cell-carcinoma

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Sporadic Papillary Renal (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Sporadic Papillary Renal Cell Carcinoma

Sporadic Papillary Renal Cell Carcinoma lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Sporadic Papillary Renal Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Sporadic Papillary Renal Cell Carcinoma is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Sporadic Papillary Renal Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Bevacizumab Biological
1 trials
Bone Scan Procedure
1 trials
Biopsy Procedure Procedure
1 trials
Atezolizumab Biological
1 trials
Biospecimen Collection Procedure
1 trials

US sites by state

Facility locations filed on Sporadic Papillary Renal Cell Carcinoma trials. A trial with sites in several states counts in each.

Texas 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New York 1 trials
New Jersey 1 trials
Maryland 1 trials
Illinois 1 trials
Georgia 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Sporadic Papillary Renal Cell Carcinoma page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Sporadic Papillary Renal Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • National Cancer Institute (NCI) sponsors the most Sporadic Papillary Renal Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sporadic Papillary Renal Cell Carcinoma condition card totals 1 registered trials; most-linked intervention Bevacizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.